Developing Countries Vaccine Manufacturers Meet in Beijing

More than 40 vaccine manufacturers from 17 developing countries, including nine from China, gathered in Beijing for the 27th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN) on September 22, 2026. The meeting, co-hosted by DCVMN and several Chinese companies, focused on global vaccine cooperation, innovation, and access.

The three-day event, held at the China World Hotel, brought together manufacturers with international organizations such as the World Health Organization, UNICEF, Gavi, and CEPI, as well as regulators and financial institutions.

DCVMN CEO Rajinder Kumar Suri emphasized the importance of the meeting as a platform for partnerships.

The discussions covered regional production, financing, and regulatory cooperation, including World Health Organization prequalification. Sessions also explored the use of artificial intelligence in research, manufacturing, and supply chains, as well as strategies to build public confidence in vaccination.

China's disease control experience provided a reference point for the discussions. An official from the National Disease Control and Prevention Administration highlighted China's achievements in maintaining polio-free status, eliminating neonatal tetanus, and being certified malaria-free by the WHO. Nine Chinese vaccines have obtained WHO prequalification and entered international procurement and supply systems. The official noted that China's self-developed EV71 inactivated vaccine, the first of its kind globally, has been approved in several Southeast Asian countries to support the prevention of hand, foot and mouth disease.

China has built a relatively complete vaccine production system with large-scale supply capacity, the official said. A number of Chinese vaccine companies actively participate in international vaccine supply, and Chinese-produced vaccines serve disease prevention and control across Asia, Africa, and Latin America.

Sinovac Group, one of the co-hosts, emphasized the industry's capabilities in supporting the disease-prevention needs of China's 1.4 billion people.

The city of Beijing also outlined its support for vaccine research and industry development, including joint research, manufacturing cooperation, and the sharing of expertise with partner countries. Vaccines and biomedicine are a stated priority of the city's high-end industrial development, with the Beijing biopharmaceutical ecosystem and vaccine industry development forming a key part of the program.

Founded in 2000, the Developing Countries Vaccine Manufacturers Network (DCVMN) is a voluntary, public health-oriented, nonprofit international organization of vaccine manufacturers from developing countries. Spanning 17 countries, the network brings together more than 40 manufacturers that contribute more than 60% of global vaccine production and supply vaccines to over 170 countries. DCVMN members have met up to 70% of vaccine demand in Africa, PAHO, and Gavi 5.0. Guided by its motto, "We connect to protect," DCVMN promotes the sustained supply of and equitable access to quality, affordable vaccines through capacity building, professional training, and technical exchanges.